Understanding how a protein called EGFR contributes to skin scarring
Epidermal Growth Factor Receptor Signaling in Fibrotic Skin Disease
['FUNDING_CAREER'] · YALE UNIVERSITY · NIH-11127442
This project explores how a specific protein called EGFR causes skin scarring in conditions like scleroderma and graft-vs-host disease.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11127442 on ClinicalTrials.gov |
What this research studies
Fibrosis, or scarring, is a serious health issue that can affect many organs, including the skin, and is a common outcome of autoimmune diseases like scleroderma. This project focuses on how a protein called Epidermal Growth Factor Receptor (EGFR) becomes active on skin cells and drives this scarring process. Researchers aim to uncover the exact steps and cellular pathways that lead to fibrosis when EGFR is activated. By understanding how EGFR interacts with other important cell signals, we hope to find new ways to stop or reverse skin scarring.
Who could benefit from this research
Good fit: Patients with fibrotic skin conditions, particularly those caused by autoimmune diseases like scleroderma or graft-vs-host disease, could potentially benefit from future treatments developed from this work.
Not a fit: Patients whose fibrosis is not related to EGFR activation or similar cellular pathways may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that target EGFR or related pathways to prevent or reverse skin scarring in fibrotic diseases.
How similar studies have performed: Previous work has identified EGFR activation in these diseases, and this project aims to build on that knowledge by exploring new aspects of its role in fibrosis.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ODELL, IAN D — YALE UNIVERSITY
- Study coordinator: ODELL, IAN D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases